Health Care • Biotechnology: Pharmaceutical Preparations
$307.02 ▼ -15.73
(-4.87%)
MKT CAP: $6.43B • VOL: 265.5K
52W L $176 52W H $327
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$258
MEDIAN
$344
MEAN
$350
HIGH
$418
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE LGND TAPE
LGND // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $371.49 | $353.07 | 2025-02-14 | $279.39 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $386.85 | $362.28 | 2025-02-06 | $288.60 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $350.00 | $337.72 | 2025-01-29 | $294.74 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $313.16 | — | 2025-01-17 | $300.88 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $270.18 | $291.67 | 2025-01-09 | $273.25 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $365.35 | $319.30 | 2024-12-18 | $267.11 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $297.81 | $310.09 | 2024-12-04 | $285.53 | -4.3% | 48% | C |